ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD70/CD3 Bispecific Antibody INCA036873

Its studies are mostly in Hematologic Neoplasms, led by Incyte.

Furthest: phase 1, since Sep 19, 20251 company-led study, 1 open or runningNext primary completion: Aug 18, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte11 open or runningphase 1since Sep 19, 2025Sep 19, 2025Aug 18, 2028phase 1 · NCT07195916

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 19, 2025First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT07195916 · 280 planned · United States, Australia, Belgium and more

Ahead

  1. Aug 18, 2028Primary completion: phase 1 study in Hematologic NeoplasmsNCT07195916

TargetBeta

CD3E →CD70 →read by rule
“A bispecific antibody and T-cell engager (TCE) targeting both the tumor-associated antigen (TAA) CD70 and the T-cell surface antigen CD3, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07195916Hematologic Neoplasms · United States, Australia, Belgium and more1RecruitingAug 18, 2028280

How it is read

Names in the registry

  • “INCA036873”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.